GRI Bio Inc
GRI0.323USD
-0.007-2.12%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.06MMarket Cap
LossP/E TTM
More Details of GRI Bio Inc Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
GRI Bio Inc Info
Ticker SymbolGRI
Company nameGRI Bio Inc
IPO dateFeb 10, 2021
CEOHertz (W. Marc)
Number of employees3
Security typeOrdinary Share
Fiscal year-endFeb 10
Address2223 Avenida De La Playa
CityLA JOLLA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92037
Phone16194001171
Websitehttps://www.gribio.com/
Ticker SymbolGRI
IPO dateFeb 10, 2021
CEOHertz (W. Marc)
Company Executives of GRI Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
111.00
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Ms. Leanne M. Kelly
Ms. Leanne M. Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. W. Marc Hertz, Ph.D.
Dr. W. Marc Hertz, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Vipin Kumar Chaturvedi, Ph.D.
Dr. Vipin Kumar Chaturvedi, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Roelof Rongen
Mr. Roelof Rongen
Independent Director
Independent Director
--
--
Mr. David Charles Baker
Mr. David Charles Baker
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Albert Agro, Ph.D.
Dr. Albert Agro, Ph.D.
Chief Medical Officer
Chief Medical Officer
111.00
--
Ms. Jenene Thomas
Ms. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Ms. Leanne M. Kelly
Ms. Leanne M. Kelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. W. Marc Hertz, Ph.D.
Dr. W. Marc Hertz, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. David Szekeres
Mr. David Szekeres
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 19
Updated: Fri, Dec 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.42%
DRW Securities, LLC
1.71%
The Vanguard Group, Inc.
0.29%
Geode Capital Management, L.L.C.
0.21%
Tower Research Capital LLC
0.07%
Other
92.30%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.42%
DRW Securities, LLC
1.71%
The Vanguard Group, Inc.
0.29%
Geode Capital Management, L.L.C.
0.21%
Tower Research Capital LLC
0.07%
Other
92.30%
Shareholder Types
Shareholders
Proportion
Corporation
5.42%
Investment Advisor
2.01%
Investment Advisor/Hedge Fund
0.21%
Hedge Fund
0.07%
Other
92.30%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
17
36.64K
1.46%
-11.84K
2025Q2
20
5.55K
0.22%
-27.52K
2025Q1
19
5.33K
0.23%
-27.51K
2024Q4
20
13.78K
9.69%
-11.29K
2024Q3
27
8.71K
9.92%
-9.69K
2024Q2
28
4.88K
16.98%
+3.17K
2024Q1
27
1.68K
35.84%
+996.00
2023Q4
32
776.00
40.40%
+67.00
2023Q3
33
1.00K
63.77%
-329.00
2023Q2
39
1.48K
108.51%
+733.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
17.00K
0.68%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
--
0%
-4.48K
-100.00%
Mar 31, 2025
Tower Research Capital LLC
3.83K
0.15%
+2.56K
+201.18%
Jun 30, 2025
Hertz (Walter Marc)
249.00
0.01%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
211.00
0.01%
--
--
Jun 30, 2025
SBI Securities Co., Ltd.
117.00
0%
--
--
Jun 30, 2025
Chaturvedi (Vipin)
111.00
0%
--
--
Jun 30, 2025
Agro (Albert)
111.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Date
Type
Ratio
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Feb 19, 2025
Merger
17→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jun 14, 2024
Merger
13→1
Jan 26, 2024
Merger
7→1
Jan 26, 2024
Merger
7→1
View more
FAQs
Who are the top five shareholders of GRI Bio Inc?
The top five shareholders of GRI Bio Inc are:
The Vanguard Group, Inc. holds 17.00K shares, accounting for 0.68% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Tower Research Capital LLC holds 3.83K shares, accounting for 0.15% of the total shares.
Hertz (Walter Marc) holds 249.00 shares, accounting for 0.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 211.00 shares, accounting for 0.01% of the total shares.
The Vanguard Group, Inc. holds 17.00K shares, accounting for 0.68% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Tower Research Capital LLC holds 3.83K shares, accounting for 0.15% of the total shares.
Hertz (Walter Marc) holds 249.00 shares, accounting for 0.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 211.00 shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of GRI Bio Inc?
The top three shareholder types of GRI Bio Inc are:
Intracoastal Capital, L.L.C.
DRW Securities, LLC
The Vanguard Group, Inc.
Intracoastal Capital, L.L.C.
DRW Securities, LLC
The Vanguard Group, Inc.
How many institutions hold shares of GRI Bio Inc (GRI)?
As of 2025Q3, 17 institutions hold shares of GRI Bio Inc, with a combined market value of approximately 36.64K, accounting for 1.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.23%.
What is the biggest source of revenue for GRI Bio Inc?
In --, the -- business generated the highest revenue for GRI Bio Inc, amounting to -- and accounting for --% of total revenue.
